Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients with purine analogue refractory disease or TP53 dysfunction still have limited treatment options and poor survival. Alemtuzumab containing chemoimmunotherapy regimens can be effective but frequently cause serious infections. We r...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Am J Hematol
Main Authors: Zent, Clive S., Taylor, Ronald P., Lindorfer, Margaret A., Beum, Paul V., LaPlant, Betsy, Wu, Wenting, Call, Timothy G., Bowen, Deborah A., Conte, Michael J., Frederick, Lori A., Link, Brian K., Blackwell, Sue E., Veeramani, Suresh, Baig, Nisar A., Viswanatha, David S., Weiner, George J., Witzig, Thomas E.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4280857/
https://ncbi.nlm.nih.gov/pubmed/24723493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23737
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים